



Submitted by:

Awny Farajallah, MD, FACP  
Vice President, Head US Medical Oncology  
Bristol-Myers Squibb Company  
3401 Princeton Pike  
Lawrence NJ, 08648  
609-302-3927; awny.farajallah@bms.com

March 6, 2018

### **NCCN Guidelines® Panel: Colon/Rectal/Anal Cancers**

Dear Panel Members,

On behalf of Bristol-Myers Squibb Company, I respectfully submit the enclosed OPDIVO® (nivolumab) prescribing information and clinical data which supports the most recent label change, that occurred on March 5, 2018 to reflect the new dosing for nivolumab to 240mg administered intravenously every 2 weeks over 30 minutes.<sup>1</sup> This information is being sent to the NCCN® Colon/Rectal/Anal Cancers Panel for your consideration.

#### **Specific Changes:**

- NCCN Guideline for Colon Cancer
  - Request for the inclusion as a footnote to COL-11 and COL-D (page 1-5 and page 9), the following: nivolumab FDA approved dose is 240mg IV every 2 weeks administered over 30 minutes until disease progression or unacceptable toxicity.<sup>1</sup>
- NCCN Guideline for Rectal Cancer
  - Request for the inclusion as a footnote to REC-11 and REC-E (page 1-5 and page 9) the following: nivolumab FDA approved dose is 240mg IV every 2 weeks administered over 30 minutes until disease progression or unacceptable toxicity.<sup>1</sup>

#### **FDA Clearance of OPDIVO® (nivolumab) (indication in Metastatic Colon Cancer):**

- OPDIVO® is indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.<sup>1</sup>

**Rationale:** The Opdivo Prescribing Information was updated to reflect the new dosing of Opdivo to 240mg administered intravenously every 2 weeks or 480mg administered intravenously every 4 weeks over 30 minutes for all indications, except for metastatic colorectal cancer which is to be dosed at 240mg administered intravenously every 2 weeks over 30 minutes.<sup>1</sup> The dosing recommendation stated in the product label is different than the dose that was administered in the registrational clinical studies that supported the current approved indications.

As part of this submission, the published literature that support the pharmacokinetic analyses for the dosing of 240 mg and a 30 minute infusion time are enclosed for your review.<sup>2,3</sup>

1. Product Information, OPDIVO® (nivolumab) injection for intravenous infusion. Bristol-Myers Squibb Company, Princeton, NJ. March 2018.
2. Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. *Ann Oncol.* 2017;28:2002-2008.

3. Waterhouse D, Horn L, Reynolds C, et al. Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153. *Cancer Chemotherapy and Pharmacology*. 2018; DOI: 10.1007/s00280-018-3527-6.

Thank you for your consideration.

Sincerely,

A handwritten signature in black ink, appearing to read "Awny Farajallah". The signature is fluid and cursive, with a long horizontal stroke extending to the right.

Awny Farajallah, MD, FACP  
Vice President, Head US Medical Oncology  
Bristol-Myers Squibb Company